Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types

BACKGROUND: PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PSPD) among patients with various solid tumor types treated by anti‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin‐Romano, Patricia, Castanon, Eduardo, Ammari, Samy, Champiat, Stéphane, Hollebecque, Antoine, Postel‐Vinay, Sophie, Baldini, Capucine, Varga, Andrea, Michot, Jean Marie, Vuagnat, Perrine, Marabelle, Aurélien, Soria, Jean‐Charles, Ferté, Charles, Massard, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163099/
https://www.ncbi.nlm.nih.gov/pubmed/32074405
http://dx.doi.org/10.1002/cam4.2797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163099/
https://www.ncbi.nlm.nih.gov/pubmed/32074405
http://dx.doi.org/10.1002/cam4.2797

Ejemplares similares